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Abstract: Laboratory diagnostics develop through differ-
ent phases that span from test ordering (pre-preanalytical 
phase), collection of diagnostic specimens (preanalytical 
phase), sample analysis (analytical phase), results report-
ing (postanalytical phase) and interpretation (post-posta-
nalytical phase). Although laboratory medicine seems 
less vulnerable than other clinical and diagnostic areas, 
the chance of errors is not negligible and may adversely 
impact on quality of testing and patient safety. This article, 
which continues a biennial tradition of collective papers 
on preanalytical quality improvement, is aimed to provide 
further contributions for pursuing quality and harmony in 
the preanalytical phase, and is a synopsis of lectures of 
the third European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM)-Becton Dickinson (BD) Euro-
pean Conference on Preanalytical Phase meeting entitled 
‘Preanalytical quality improvement. In pursuit of har-
mony’ (Porto, 20–21 March 2015). The leading topics that 
will be discussed include unnecessary laboratory testing, 
management of test request, implementation of the Euro-
pean Union (EU) Directive on needlestick injury preven-
tion, harmonization of fasting requirements for blood 
sampling, influence of physical activity and medical 
contrast media on in vitro diagnostic testing, recent evi-
dence about the possible lack of necessity of the order of 
draw, the best practice for monitoring conditions of time 
and temperature during sample transportation, along 
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with description of problems emerging from inappropri-
ate sample centrifugation. In the final part, the article 
includes recent updates about preanalytical quality indi-
cators, the feasibility of an External Quality Assessment 
Scheme (EQAS) for the preanalytical phase, the results of 
the 2nd EFLM WG-PRE survey, as well as specific notions 
about the evidence-based quality management of the pre-
analytical phase.
Keywords: harmonization; laboratory errors; preanalyti-
cal variability; standardization.
Introduction
Laboratory diagnostics, a crucial part of the clinical deci-
sion-making, is articulated in various phases that span 
from test ordering (pre-preanalytical phase), collection 
of diagnostic specimens (preanalytical phase), sample 
analysis (analytical phase), results reporting (postanalyti-
cal phase) and interpretation (post-postanalytical phase). 
Although laboratory medicine seems overall less vulner-
able to slips, lapses, mistakes and violations than other 
clinical and diagnostic areas, the chance of errors is not 
negligible and may generate adverse consequences on 
both the quality of testing and patient safety [1, 2]. Several 
lines of evidence now attest that the vast majority of labo-
ratory errors emerge from the manually intensive activi-
ties of the preanalytical phase, especially those related 
to collection, handling, transportation, preparation and 
storage of diagnostic specimens [3]. The frequency of ana-
lytical errors is consistently lower, and mainly attributable 
to instrument malfunctioning, inappropriate calibration, 
violation of quality control rules and analytical interfer-
ence [4]. Postanalytical errors have an intermediate fre-
quency between preanalytical and analytical mistakes, 
and mostly entail misinterpretation of test results and 
delay in reporting of critical data [5] (Figure 1). Most of 
the problems that arise throughout the testing process are 
preventable, by adoption of a multifaceted strategy based 
on a policy of quality, which should entail continuous 
education, standardization of activities, implementation 
of technological advances that are effective to prevent or 
timely identify preventable mistakes, along with effective 
communication with all the stakeholders of laboratory 
services [6].
This article, which continues a biennial tradition of 
collective papers on preanalytical quality improvement 
[7, 8], is aimed to provide further contributions for pur-
suing quality and harmony in the preanalytical phase, Figure 1 The iceberg of laboratory errors.
and is a synopsis of lectures of the third European Fed-
eration of Clinical Chemistry and Laboratory Medicine 
(EFLM)-Becton Dickinson (BD) European Conference 
on Preanalytical Phase meeting entitled ‘Preanalytical 
quality improvement. In pursuit of harmony’ (Porto, 
20–21 March 2015) (http://www.preanalytical-phase.
org/node/1). The leading topics that will be discussed 
include unnecessary laboratory testing, management of 
test request, implementation of the European Union (EU) 
Directive on needlestick injury prevention, harmoniza-
tion of fasting requirements for blood sampling, influ-
ence of physical activity and medical contrast media 
on in vitro diagnostic testing, recent evidence about the 
possible lack of necessity of the order of draw, the best 
practice for monitoring conditions of time and tempera-
ture during sample transportation, and description of 
problems emerging from inappropriate sample centrifu-
gation. In the final part, the article provides some recent 
updates about preanalytical quality indicators, the feasi-
bility of an External Quality Assessment Scheme (EQAS) 
for the preanalytical phase, the results of the second 
survey of the EFLM Working Group on preanalytical vari-
ability (WG-PRE), as well as specific notions about the 
evidence-based quality management of the preanalytical 
phase. We hope that the readership of Clinical Chemistry 
and Laboratory Medicine will find interest in the con-
tents of his article.
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The leading role of the EFLM 
in  harmonizing the preanalytical 
phase of laboratory testing
Although laboratory medicine has implemented some 
extraordinary developments over the past decade, the 
overall benefit of those changes to the quality of the 
healthcare will not reach its full potential if both the pre- 
and postanalytical phases (in addition to the analytical 
phase) of the total testing process are not harmonized. In 
addressing harmonization of preanalytical phase in labo-
ratory testing, a recent report states that this is currently 
not coordinated on an international basis [9]. To overcome 
this problem, the EFLM and its WG-PRE have decided to 
take the lead in catalyzing various international projects 
in the field [10, 11]. In addition, EFLM has raised aware-
ness about the need to harmonize the postanalytical 
phase of testing, and the Federation has recently estab-
lished a new WG for Harmonization of the Total Testing 
Process (WG-H) to fulfill this goal, and with the specific 
aim to become the facilitator and coordinator for existing 
initiatives at national level in various countries.
With the European Conference on Pre-analytical 
Phase, the EFLM through its WG-PRE is specifically 
addressing preanalytical issues, such as appropriate test 
selection and test profile requesting, optimization of 
training, sample handling and application of quality indi-
cators. The EFLM strongly believes that harmonization 
of each of these issues may markedly reduce the poten-
tial risk of preanalytical errors and substantially improve 
patient safety. The EFLM is also calling for a joint action 
by laboratory professionals, healthcare practitioners, 
manufacturers and standard writing bodies to support 
the definition of universally applicable standards for the 
preanalytical phase and their worldwide implementation. 
The EFLM is finally willing to take responsibility to act 
as a convener for a dialog between all interested parties. 
All stakeholders working in the field should be invited to 
join a dialogue to establish standardized procedures for 
preanalytical processes that, in turn, standard writing 
bodies should take into account in updating the existing 
recommendations.
Unnecessary laboratory tests – 
a matter of concern?
In a systematic review of laboratory clinical audits 
examining the inappropriateness of laboratory testing 
published nearly 15 years ago, van Walraven and Naylor 
found rates comprised between 5% and 95%, thus clearly 
demonstrating the difficulty of accurately estimate the 
burden of inappropriateness [12]. A more recent analy-
sis exploring the iceberg of laboratory inappropriateness 
has concluded that overuse or inappropriate utilization 
of laboratory resources may span from 23% to 67%, the 
largest part being attributable to medical liability con-
cerns [13].
Inappropriateness in the context of laboratory diag-
nostics is deemed to be tests which could be avoided with 
no detriment to patient care. The cost of these tests to a 
healthcare system can be estimated, although it is impor-
tant to consider the financial context of a healthcare 
economy. In integrated healthcare economies, only the 
marginal (i.e., reagent) cost is relevant. Total billing costs 
are not relevant to institutions, such as the UK National 
Health Service, as they include laboratory overheads 
which would continue to be charged unless the laboratory 
itself became unnecessary. Definitions of appropriateness 
vary from tests which are manifestly not necessary, to 
those producing normal results which nevertheless may 
be entirely appropriate in the clinical context. However, 
comparative benchmarking of activity shows differences 
between primary care test submissions of up to 2000% 
between top and bottom deciles of requesting activity for 
some tests, which suggests that something more should 
be done [14]. Even when taking into account assorted 
patient demographics, specific practice subspecialist 
interests and social depravation indices, these differences 
still remain, thus suggesting that the main driving force 
is clinical decision-making. Whilst individual test costs 
are relatively low, the cumulative impact of multiple inap-
propriate testing is significant. Moreover, most cost esti-
mates do not include the ‘on-costs’ of further referrals and 
investigations, nor indeed the personal harm caused by 
abnormal tests (i.e., tumor markers) which may have been 
requested unnecessarily in the first instance and produce 
false positive results [15].
Various initiatives, such as the UK Quality and Out-
comes Framework (QOF), have endeavored to set certain 
minimum standards for some testing activity with a finan-
cial incentive, which have helped to avoid undertesting, 
although few initiatives have been enacted to address the 
issue of overtesting. The appropriateness of testing seems 
better in well defined areas, such as diabetes or lipid man-
agement, although significant differences continue to 
exist. Testing in less well defined areas remains far less 
consistent. Therefore, inappropriate use of testing (both 
under and overtesting) remains a problem, and initiatives 
are needed to address this issue.
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Managing test requesting – 
practical experience
Improvements in public health care have resulted in 
enhanced life expectancy and increased health expendi-
ture, which are mainly attributable to a frequently unjus-
tified intensity of services. Health spending has grown 
faster than our ability to generate resources, and the 
ongoing financial crisis has exacerbated this effect. The 
reaction to this has been the need to ‘cut back’ health-
care costs. Accordingly, health managers have identi-
fied laboratory diagnostics as an easy and attractive 
opportunity to reduce the overall healthcare expendi-
ture [16, 17], which is however minimal (i.e.,  < 2%) [18]. 
In this evolving scenario, evidence-based (laboratory) 
medicine plays a crucial role, as it would contribute to 
generate a paradigm shift, from the concept of ‘demand 
restriction’ to that of ‘demand adequacy’. It is undeni-
able that this strategy generates economical benefits 
both in the short- and long-term, especially regarding 
the leading healthcare indicators (i.e., efficiency and 
effectiveness).
The group of laboratories belonging to the public 
network of the Catalonian Health Service has recently 
developed a local project with the aim of investigating 
demand variability across different facilities, based upon 
the premise that information on this source of variability 
may be regarded as the first step to improve the clinical 
usefulness of diagnostic testing. Practical examples of 
implementing improvement strategies obtained by this 
group are being collected and classified according to 
a reliable scheme describe elsewhere [19, 20]. In brief, 
these entail general and/or specific strategies guided 
by studies of variability and/or application of evidence-
based medicine. Prelaboratory strategies include edu-
cation of stakeholders (especially patients) by means of 
written information and web sites edited or reviewed by 
health technicians and laboratories professionals. The 
cooperation and involvement of clinicians is achieved 
by introducing some key aspects of utilization of labo-
ratory resources in medical and nursing university core 
curricula. The participation in interdisciplinary groups 
is promoted, with dissemination of information on labo-
ratory tests and involvement in clinical tests selection. 
Other important strategies that are adopted include those 
related to the software used by clinicians to prescribe 
testing (i.e., facilitation of access to information and train-
ing, communication of test cost at the time of request, 
prescription guided by expert systems based on specific 
protocols or profiles, limits to repeat testing practice, 
elimination of obsolete or redundant testing). The quality 
indicators of test prescription and cost are reported to the 
clinicians. Additional within-laboratory strategies include 
deletion or generation of tests. Finally, a paradigmatic 
example of postlaboratory strategy put into action by the 
public network of the Catalonian Health Service entails 
the clinical impact evaluation of laboratory data. Quality 
indicators of test request used by the group are considered 
as strategic. Some examples include number of requests 
per 1000 inhabitants (Primary Health Care), number of 
tests per request (stratified by patient type), and the ratios 
between interrelated tests.
Implementing the EU Directive on 
needlestick injury prevention – 
2 years of experience
The purpose of Directive 2010/32/EU is to protect workers 
in healthcare settings from injuries caused by all medical 
sharp devices, and from their consequences such as occu-
pational human immunodeficiency virus (HIV), hepati-
tis C virus (HCV) and hepatitis B virus (HBV) infection, 
by setting up integrated policies in risk assessment, risk 
prevention, training, information, and monitoring [21]. 
The deadline for its transposition into national law by the 
28 Member States has expired in May 2013. As of Febru-
ary 2014, 24 Member States had communicated national 
transposing measures to the Commission, whose con-
formity is currently being assessed [22].
An online survey conducted in October 2013 by the 
European Federation of Nurses Associations with almost 
7000 respondents from the 28 Member States (87% 
nurses), showed that the Directive had a positive impact 
in the daily practice and clinical environment of the 
health professionals, with 70% reporting availability of 
safety-engineered devices (SED) (blood collection 44%, 
infusion 31%, injection 39%), 78% having received basic 
information at the workplace, and 95% feeling a clear 
responsibility in reporting. However, respondents identi-
fied areas being less covered, particularly specific educa-
tion on sharp injuries prevention (53%), performance of 
risk assessment at the workplace (40%), and awareness 
campaigns (37%). Moreover, 30% reported needing more 
instructions on postexposure management. Even more 
importantly, 41% of the respondents had already suffered 
a needlestick incident (NSI) [23].
In November 2013, a European Federation of Public 
Service Unions (EPSU) and European Hospital and 
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Healthcare Employers’ Association (HOSPEEM) survey 
reported that the main alterations to existing legislative 
texts revolved around issues, such as the ban on recap-
ping, requirements for more specific risk assessment and 
provision of preventative vaccinations. The more wide-
spread introduction of SED was also considered to be a 
likely consequence of the new legislation in a number of 
countries (albeit based on risk assessment). The SED cost 
was considered to be a potential challenge in some coun-
tries, particularly in smaller Member States with signifi-
cant budgetary restrictions. However, the implementation 
of all required preventive interventions, and not only of 
SED, may be affected by budgetary cuts. As an example, 
Romania reported the cessation of mandatory HBV vacci-
nation of healthcare staff, now only offered in areas con-
sidered at highest risk [24].
SED play an important role in decreasing injuries, 
when implemented within an integrated approach to 
risk prevention. A recent study in Europe showed a sig-
nificant (i.e., –60%) reduction in the NSI rate from blood-
collection devices even in hospitals already using a safety 
device, when a new generation, semi-automated device 
with in-vein activation was adopted. Design and ease-of-
use have been demonstrated to strongly influence SED 
efficacy and increase their acceptance. As such, the joint 
EPSU-HOSPEEM Project conclusions include a recom-
mendation for SED to be developed with the assistance of 
practitioners.
Long lasting experiences in Italy, France and Spain 
show that an integrated approach is the most effective 
means to work towards a sustainable reduction of sharps 
injuries. The Directive has brought an important step 
forward towards ensuring the implementation of such an 
integrated approach, but to ensure its success, all health-
care personnel should be aware of, and comply with, the 
legislation that has come into force as a result, with a 
strong support from healthcare administration.
Harmonization of fasting  
requirements for blood sampling
Fasting is a well known term implying that the patient 
must refrain from certain items (e.g., food, alcohol, 
coffee, smoking, perhaps even medication). Unfortu-
nately, however, these items are not well described or 
harmonized, either internationally or nationally [25]. 
Furthermore, the duration of fasting is not well defined 
despite the knowledge that many parameters change over 
time (e.g., the triglycerides, which actually increase after 
a certain time period of fasting as results of fatty acid 
metabolism). In general, many clinicians erroneously 
think that fasting is only needed for a very small pallet of 
analyses, but it can also have a clinically significant effect 
on several hematological [26], hemostatic [27], as well as 
biochemical parameters [28]. Finally, patients tend to be 
misinformed about the fasting requirements for labora-
tory blood testing [29], which very likely can be due to the 
lack of a fasting definition and misleading information 
from their requesting physician.
The lack of a general fasting definition is hence a 
clinically significant problem – in daily routine as well 
as in research studies – and the WG-PRE has put forward 
a number of recommendations, one of which includes a 
harmonized and more precise definition of fasting [30]. 
Another of these recommendations concerns the pro-
fessional biochemistry associations and the laboratory 
professionals, whom are called upon in order to take 
the responsibility for this harmonization process (e.g., 
by having more rigid acceptance criteria to the fasting 
samples and by spreading the information regarding a 
harmonized fasting definition to their clinicians).
Physical activity as an important 
preanalytical variable
Sports and exercise medicine is broadly dependent upon 
physiology and laboratory medicine data. The biochemi-
cal and hematological parameters are mainly used in 
sports medicine for evaluating the health status of recrea-
tional and professional athletes, for preventing infectious 
diseases and injuries, for evaluating performances and, 
finally, for detecting the use of illicit and unethical sub-
stances or methods [31].
The analytical process and the global quality of labo-
ratory diagnostics are both strongly influenced by several 
aspects of the preanalytical phase and, among these, a 
particular source of preanalytical variation is indeed rep-
resented by physical exercise [32]. This variable impacts 
on laboratory testing either directly (i.e., by modifying 
human biology and metabolism) or indirectly (i.e., for 
intake of food and beverages, drugs or food supplements). 
Interestingly, the effect of exercise extends far beyond 
the typical boundaries of diagnostic testing in blood, to 
embrace different body fluids, such urine and saliva, as 
these biological matrices are widely used for obtaining 
data for antidoping testing and monitoring exercise per-
formances, especially when a high number of drawings is 
necessary [33].
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The preanalytical phase became particularly crucial in 
antidoping controls after the introduction of the so-called 
athlete biological passport (ABP). This algorithm is based 
on values of hemoglobin and reticulocytes, evaluated over 
time in the single athlete. In this setting, transportation, 
refrigeration and stability of hematological values are 
essential to obtain correct data, thus representing a reli-
able ground for appropriate statistical interpretation [34].
The stability of hematological parameters is particu-
larly crucial to guarantee accurate and reliable data for 
implementing and interpreting the ABP. In this model, 
the values of hemoglobin, reticulocytes and out-of-doping 
period (OFF)-score (hemoglobin-60√reticulocytes) are 
used to monitor the possible variations of these param-
eters, as well as for comparing the thresholds developed 
by the statistical model for the single athlete on the basis 
of its personal values and the variance of parameters in 
the modal group. The stability of hematological parame-
ters might be improved independently from the analytical 
methodology, by refrigeration of specimens [35].
It is noteworthy that a mishandled preanalytical man-
agement of athletes’ samples has adjunctive implications 
in sports medicine over those of conventional laboratory 
testing, as data collected for antidoping controls are also 
specifically used to identify cheating and then determine 
sport or civil sanctioning [36]. For example, in sport and 
court trials, plasma removal from EDTA tubes before cell 
counting and hemoglobin measurement, stability of mean 
corpuscular volume before hemoglobin measurement, and 
influence of diet and exercise on total growth hormone 
(GH) (i.e., for definition of hormone variant 22K and 20K), 
have been used as arguments of the final judgment.
Interference of medical contrast 
media on laboratory testing
The use of medical contrast media is very frequent in diag-
nostic imaging, with the aim to enhance the contrast of 
body organs or fluids, thus ultimately improving the visi-
bility of internal structures with imaging techniques, such 
as X-ray, computer tomography (CT), magnetic resonance 
imaging (MRI) or ultrasounds. These pharmacologic com-
pounds conventionally include barium sulfate, organic 
iodine molecules, such as iohexol, iodixanol and ioversol, 
or gadolinium contrast agents which can be ionic, neutral, 
albumin-bound or even polymeric [37].
Since their introduction in clinical practice, the 
potential side effects and the interactions with drugs 
have been regarded as the leading medical concerns of 
contrast media. Nevertheless, several lines of evidence 
attest that these agents may also jeopardize patient safety 
by impairing the quality of in vitro diagnostic testing, as 
a number of potential interferences have been reported 
with some laboratory tests [38]. In particular, iodinate 
contrast media have been reported as a source of incom-
plete gel barrier formation and serum or plasma sepa-
ration in primary blood tubes [39], of abnormalities in 
electrophoresis of serum proteins (e.g., emergence of 
extra and unusual peaks), as well as of positive bias in 
measurement of cardiospecific troponin I with certain 
immunoassays. Interference has also been reported in 
patients receiving gadolinium contrast agents [38]. These 
specifically include a negative bias in the measurement of 
serum or plasma calcium with some colorimetric assays 
(i.e., those based on ortho-cresolphthalein) along with a 
positive bias in the assessment of the same analyte with 
Arsenazo reagents, a negative bias in the measurement of 
angiotensin converting enzyme (ACE) and zinc (especially 
using colorimetric assays), along with a positive bias in 
creatinine measured with Jaffe reagents, total iron binding 
capacity (TIBC) using the ferrozine method, magnesium 
using calmagite reagent and selenium by mass spectrom-
etry techniques [38]. In patients receiving Patent Blue V 
(i.e., a synthetic inert compound that is conventionally 
employed during cancer surgery for detecting potential 
lymph node localization), some degree of interference has 
been observed when measuring serum indices and meth-
emoglobin [38].
It is noteworthy that a comprehensive description 
about the potential interference in laboratory testing 
is frequently absent from information supplied by the 
manufacturer of medical contrast agents (or only limited 
to certain type of reagents and/or analytes, at best). 
As such, a specific assessment of potential bias may be 
advisable, in order to define whether a certain type of con-
trast medium may interfere with reagents locally used for 
testing by the single facilities. Moreover, due to the fact 
that the elimination half-life of medical contrast media is 
usually comprised between 1 and 3 h, blood drawing after 
such period of time may be advisable in patients receiving 
these agents [38].
The order of draw – myth or science?
National and international guidelines, such as those 
issued by the Clinical Laboratory Standards Institute 
(CLSI) [40] or the World Health Organization (WHO) [41], 
recommend that an order of tubes should be followed 
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during blood drawing, i.e., blood culture/sterile tubes 
first, followed by plain tubes/gel tubes, and then tubes 
containing additives. This specific strategy is aimed to 
prevent contamination of sample tubes with additives 
from previous tubes, such as sodium citrate or more com-
monly potassium-EDTA (K-EDTA).
These recommendations are mostly based on a case 
report published by Sun in 1977 [42], and a follow-up 
study by Calam and Cooper in 1982 [43], which reported 
that an incorrect order of draw caused hyperkalemia and 
hypocalcemia, two surrogate markers of in vitro K-EDTA 
sample contamination. The authors did acknowledge, 
however, that contamination with additives only occurred 
during difficult venipunctures and could not be replicated 
under ideal phlebotomy conditions. It has been defini-
tively demonstrated, by measuring EDTA, that reverse 
order of draw of blood samples using closed loop phle-
botomy systems does not cause EDTA contamination [44]. 
This has been subsequently confirmed in another study 
[45]. Although it seems difficult to reconcile the conflict-
ing results emerged from different studies, it may be that a 
random order of draw using poor sample collection tech-
niques and/or during difficult venipunctures may result 
in cross-contamination of sample tubes, thus ultimately 
jeopardizing the quality of testing [46, 47]. This idea is 
supported by a study of Berg et al. [48], which showed that 
only 6% of blood collections were performed using the 
conventional manufacturer prescribed closed loop system 
in a major emergency department in the UK. Lima-Oliveira 
et al. also recently described a patient case in which devi-
ation from the standard blood sampling procedure and 
recommended order of draw resulted in sample EDTA con-
tamination with subsequent increase in potassium and 
decrease in calcium concentration [49].
In general, a significant bias may be typically observed 
in the serum values of calcium, chloride, lactate dehydro-
genase (LDH), magnesium and potassium starting from 
5% contamination with K-EDTA blood, whereas the serum 
values of sodium, phosphate and iron may be biased start-
ing from 29% contamination with K-EDTA blood [47].
It has been earlier shown that contamination with 
EDTA (and, to a lesser extent, with sodium citrate) is still 
relatively frequent and may be difficult to identify [50]. As 
this is not probably due to the use of a random order of 
draw of blood samples in a closed loop system, it seems 
plausible that in vitro K-EDTA and citrate contamination 
may occur with open blood collection systems by syringe 
needle or syringe tip contamination when delivering col-
lected blood into K-EDTA or citrate sample tubes before 
other tubes, and by direct transfer of blood from K-EDTA 
or citrate containing tubes to other sample tubes [51]. The 
latter circumstance can be easily detected by the labora-
tory staff, because it would generate gross abnormalities 
in surrogate markers. Nevertheless, more subtle contami-
nation is possible with the former condition, which is 
less easily identifiable using these markers and may also 
cause misdiagnosis and/or mismanagement of patients. 
In summary, 1) there is currently not enough evidence to 
support the recommended order of draw (if closed loop 
venipuncture systems are used); 2) evidence is lacking to 
confirm that the recommended order of draw helps avoid 
sample cross-contamination; and 3) sample cross-con-
tamination is not rare, and further studies are needed to 
investigate and confirm possible mechanisms of sample 
cross-contamination in order to implement focused and 
appropriate preventive measures.
Monitoring the time and temperature 
conditions of sample transport
The increasing pressure to cut costs in healthcare 
organizations has affected the laboratory activities and 
workflows, wherein consolidation processes have lead 
to transportation of large numbers of specimens from 
peripheral collection sites to the core laboratory [52]. As 
a consequence, there is an increasing need for systems 
able to assure quality and safety in biological sample 
transportation, as well as to monitor the risk of errors in 
this step. In fact, this part of the preanalytical process 
is widely recognized as a major factor that contributes 
to delays in returning high quality clinical laboratory 
results for both inpatients and outpatients testing, 
although scarce evidence is available in the current lit-
erature on this issue [53].
International standards for accreditation emphasize 
the importance to check and assess the most critical phases 
in sample transportation by using specific procedures for 
verification of each step, thus including: 1) time between 
blood collection and specimen analysis; 2)   temperature 
and time of samples storage from collection to analysis; 
3) packaging criteria and sample positioning during trans-
port; and 4) identification and documentation of accept-
ability/rejection criteria [54].
The Department of Laboratory Medicine of the Univer-
sity Hospital of Padua, which provides inpatient and out-
patient services for samples collected from 21 centers in a 
broad area in North East Italy, has adopted an integrated 
system consisting of secondary and tertiary containers, a 
device for temperature and time recording, and a system 
manager that allows to accept or reject biological samples 
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through immediate visualization of recorded data that are 
compared to accurately defined conditions [55, 56].
The results collected in  > 5 years of experience demon-
strated the efficacy of the system in standardizing the con-
ditions of sample transportation, allowing a significant 
decrease of variations recorded in samples transported 
from long- and short-term peripheral centers, particu-
larly for some critical tests, such as potassium, calcium, 
activated partial thromboplastin time (APTT) and hemo-
globin. It is also noteworthy that, along with technological 
facilities, it is of essential importance to accurately train 
the personnel involved by setting specific standard oper-
ating procedures (SOPs), which would enable the adop-
tion of objective criteria in evaluating transport conditions 
and monitoring compliance in the daily routine practice. 
Some specific quality indicators were finally introduced 
in the quality system in order to produce data, which 
allowed monitoring and improvement of performance of 
the implemented integrated system.
Centrifugation – is there room 
for improvement?
The purpose of centrifugation is to separate the compo-
nents of a sample according to their density, to ensure 
that analytes and cells of interest can be accurately 
assessed. Inappropriate centrifugation conditions may 
as a minimum necessitate re-centrifugation of sample, or 
worse potentially lead to inappropriate results [57]. The 
quality of sample separation and its impact on labora-
tory workflow is mainly influenced by sample preparation 
(sample clotting, time before centrifugation, tempera-
ture), sample type (serum or plasma, with or without sep-
aration media), centrifugation equipment (swing bucket 
vs. fixed angle), and centrifugation conditions (speed, 
time, temperature, acceleration and deceleration). Never-
theless, there is often a need to balance these important 
considerations against the throughput and turnaround 
time targets of the laboratory.
Centrifugation requirements vary depending on 
sample type. For coagulation, centrifugation is the key 
factor in minimizing the levels of cells in the plasma, 
and recommendations for the creation of platelet-poor 
plasma and platelet-free plasma exist [58]. For chemistry 
samples, the separation of the cells from the superna-
tant will be impacted by whether it is a plasma or serum 
sample. Serum samples are essentially ‘non-cellular’ 
after the centrifugation process, whereas plasma contains 
varying levels of cells that in part explain the analytical 
differences that are observed between serum and plasma 
analytes [59, 60]. The impact of centrifugation on serum 
and plasma is further evident with the introduction of a 
separation medium (e.g., gel or other inert separators), 
defining how the gel moves to its position of equilib-
rium and the level of residual cells that are trapped in 
the supernatant. Stringent centrifugation criteria are also 
mandatory for hemostasis testing, wherein the use (or 
non-use) of the centrifuge brake [61] or different centrif-
ugation forces [62] have a substantial impact on sample 
quality. Recent developments, such as the use of mechani-
cally based separators that can ensure the sedimentation 
of cells continues throughout the centrifugation process, 
further increasing sample quality and its potential use for 
a broader array of applications.
As laboratories become more automated, managing 
an efficient sample processing step is a key requirement 
in order to maximize the return on investment with front 
end automation systems. There are a number of workflow 
processes that can be employed to improve sample pro-
cessing. The use of plasma samples for chemistry analy-
sis avoids the need to ensure the specimen is completely 
clotted prior to centrifugation. The centrifugation process 
is often the rate-limiting step in a laboratory, so that 
manufacturers of blood collection tubes are providing 
broad centrifugation conditions that maximize the use of 
high speed and, therefore, short duration centrifugation 
conditions that can be achieved using some platforms 
[63]. However, for all the different sample types there are 
rather diverse recommended centrifugation conditions, 
thus making standardization challenging. A recent study 
showed how the centrifugation conditions for chemistry 
samples can be utilized for coagulation parameters in 
order to maximize the use of their automated workflow 
and avoid inefficient parallel workflows [64].
In order to achieve the appropriate centrifugation 
with the best sample quality, meet the laboratories turna-
round time targets and maximize workflow efficiencies, 
careful consideration of sample preparation, sample type, 
centrifugation equipment and centrifugation conditions is 
advisable.
Preanalytical quality indicators
Clinical quality indicators (QIs) are intended to measure 
the extent to which set targets are achieved, and also 
provide a quantitative basis to achieve improvement in 
care and, in particular, in laboratory services [65–67]. QIs 
are hence essential requirements for medical laboratory 
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accreditation according to the International Standard (ISO 
15189: 2012). The current lack of attention to extra-labora-
tory factors and related quality indicators prevent clinical 
laboratories from effective improvement in total quality 
and error reduction projects. Errors in the preanalytical 
phase may account for 60%–75% of all laboratory errors, 
and have been traditionally classified as those pertaining 
to sample or patient identification and to unsuitable spec-
imens. However, according to the International Standard 
for Medical Laboratory Accreditation and the need for a 
patient-centered view, some innovative QIs are needed. 
In particular, measurement of the appropriateness of 
test request and request forms, as well as the quality of 
specimen transportation, is urgently needed. The model 
of QIs developed by a working group of the International 
Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) is a valuable starting point to promote the harmo-
nization of available QIs [68, 69], but further efforts have 
been done to reach a consensus on the roadmap for har-
monization. In particular, a preliminary consensus on the 
list of available QIs and on the reporting system has been 
recently achieved, and recently published in this journal 
[70]. Further activities shall be aimed towards raising 
the awareness of all stakeholders and to highlight the 
importance of QIs for improving the quality of laboratory 
services and patient safety. Simplification of the current 
model of QI by identifying a selection of several ‘manda-
tory’ indicators seems to be the reasonable compromise 
for laboratories worldwide [71].
External Quality Assessment 
Schemes for preanalytical phase
Several studies have described the most frequent errors in 
the different phases of the total testing process of labo-
ratory diagnostics, and a number of schemes for registra-
tion of errors and subsequent feedback to participants 
have also been conducted for decades by External Quality 
Assessment (EQA) organizations operating in most coun-
tries. In ISO 15189 [72], the accreditation standard for 
medical laboratories, it is stated that ‘External quality 
assessment programmes should check the entire exami-
nation process, including pre- and post-examination 
procedures’. So far, EQA organizations have focused on 
the analytical phase, and most of them do not offer pre-
analytical EQAS, as it is inherently more challenging to 
perform and standardize programs targeting the pre-
analytical phase. However, some ongoing EQA programs 
for the preanalytical phase do exist, and a trend is also 
emerging among the EQA organizers to place major focus 
on this area [73]. Basically, the methods can be divided 
into three different types. Type 1: Registration of proce-
dures could be done by circulation questionnaires, aimed 
at collecting information on how the laboratories handle 
different parts of the preanalytical phase, e.g., which cri-
teria are used for sample rejection. Type 2: These schemes 
are similar to usual analytical EQAS, but the circulated 
material simulates some kind of preanalytical error (e.g., 
hemolyzed serum) [74]. Case histories can be distributed 
together with the EQA samples to elucidate how these 
samples are dealt with, and how the results are commu-
nicated to the physicians. Type 3: Register actual preana-
lytical errors and relate these to QIs. The EQA organization 
suggests QIs related to preanalytical errors/adverse events 
and develops a common registration system that the labo-
ratories should use to report their data regularly over a 
given period. The different types of approach have differ-
ent focus and different challenges regarding implementa-
tion, and a combination of the three is probably necessary 
to effectively detect and monitor the broad range of errors 
occurring in the preanalytical phase. The feedback report 
for all the different types should also include a compari-
son of laboratory result to those of all participants, along 
with an overview of existing guidelines/recommendations 
and recent publications and advice on how to minimize 
errors.
Results of the second EFLM WG-PRE 
survey – compliance to the CLSI 
H3-A6 guidelines
Laboratory results following venous blood sample collec-
tion and analysis are important in the clinical diagnosis 
and treatment of patients [75]. Errors during phlebotomy 
are a common contributor to diagnostic errors in the total 
testing process [76]. Venous blood specimen collection 
is in addition most often not under the supervision and 
control of the laboratory, but is performed elsewhere in the 
healthcare organization. Therefore, lower sample quality 
may potentially affect results, so that the measured value 
does not represent the patient condition in vivo.
Guidelines on correct venous blood specimen collec-
tion practice, such as the commonly used H3-A6 guide-
line issued by the CLSI in 2007 [40], have many discrete 
steps, all of which can be subject to error and are to a 
large extent focused on patient and collectors safety at 
the collection moment and not on the overall patient 
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safety effects of a bad sample collection or sample han-
dling following analysis. The guidelines in addition does 
not contain risk evaluation of the different steps and also 
lacks advice on how to best implement and sustain guide-
line practices.
The test requests along with the blood drawing pro-
cedures should always adhere to medical guidelines. 
However, in practice, venous blood sample collection 
does rarely fully conform to the published guidelines, and 
so interventions may be needed to reduce patient safety 
risks. Individual [77], as well as organizational external 
factors [78], have an impact on guideline non-conformity. 
Guideline adherence may be improved by education and 
training [79], whereas accreditation of venous blood spec-
imen collection has only marginal effects.
A first WG-PRE European survey assessed the pres-
ence and compliance with national guidelines and the 
educational level and staff category by which phlebot-
omy was performed [80]. It identified a continuing need 
to assess compliance with guidelines, to adapt the exist-
ing CLSI H3-A6 document to make it more suitable for use 
in specific countries and to institute training programs 
for phlebotomy practitioners. Therefore, the WG-PRE 
conducted an observational study of phlebotomy pro-
cedures using a defined checklist to better understand 
the practices and procedures that take place in clinical 
institutions.
Key issues were chosen from the CLSI guideline by all 
WG members and addressed in a 29-items observational 
study checklist with yes/no answers. Experienced staff 
members in 12 European countries (mean audits, n = 33) 
audited as many as 336 venous blood sample collections 
in emergency, outpatient and clinical ward settings. A 
risk-occurrence analysis of the individual phlebotomy 
steps was created from observed error occurrence and 
WG members grading of harm severity. A risk-occurrence 
chart was created, with an acceptable ‘green’ risk region, 
as low as reasonable practicable ‘yellow’ risk region, 
and an intolerable ‘red’ risk region demanding corrective 
action(s).
In the observation study, the key issues in the ‘red 
region’ which had the highest combination of impact and 
probability were questions Q4 (patient identification), 
Q25 and Q26 (test tube labeling). Identification errors (Q4) 
were more frequent in emergency and outpatient settings, 
compared to clinical wards. The identification errors were 
observed to be less frequent, but were assessed as causing 
the major patient safety risk, due to a potential high risk 
of harm severity. The Q25 and Q26 were also in the ‘red 
zone’ due to their substantially high frequency and degree 
of potential harm to the patient. Labeling blood tubes 
after sampling and not in the presence of the patient was 
a moderately frequent error in the study, but was assessed 
as being possibly life threatening. This issue is therefore of 
critical importance, highly relevant and obviously shows 
room for improvement.
Modifying staff behavior to conform more closely to 
practice guidelines and other recommended practices has 
proved to be a challenging enterprise [81]. One reason is 
that efficient and accurate methods of measuring adher-
ence are missing as they are essential for policies and 
programs aiming to improve adherence. Questionnaires 
have successfully been used to monitor venous blood 
specimen collection adherence to guidelines [82]. Obser-
vational studies are seldom used, but have the advantage 
of direct observation of specimen collection errors and 
are also able to assess the error frequency for each key 
issue when performed in a larger scale as in this study. A 
severity grading to the observed error frequency was also 
included, to get an overall risk assessment and indication 
on the most critical practice steps, as well as when correc-
tions should be implemented.
In the risk analysis, patient misidentification fell 
out as an intolerable risk. Misidentification is not easily 
detectable, and reporting of identification errors may 
cause blame for the personnel. Improving patient iden-
tification is an ongoing challenge in all types of blood 
collection procedures and also a critical issue in other 
healthcare areas [83]. Another intolerable risk was the 
practice of labeling the test tube at a later occasion away 
from the patient.
Recent studies on clinical practice guideline adher-
ence have mainly focused on the organizational aspect. 
Investigations aimed to identify reasons for individual 
hazard behavior that might explain habitual choices to 
ignore important safety rules are scarce. It seems hence 
important to balance organizational and individual 
factors to ensure the best possible conditions for a culture 
that promotes safe care.
The adoption of clinical practice guidelines is 
affected by several issues, including the way they are 
implemented. Important factors for improving guide-
lines adoption include the evidence that the context is 
accessible to change, the appropriate monitoring and 
feedback mechanisms, and the available time for per-
sonnel to discuss research findings. Repeated local 
observational studies with error frequency assessment 
and risk analysis of venous blood specimen collection 
errors combined with feedback, discussions and reflec-
tion amongst phlebotomy personnel seems to be an 
efficient strategy to implement and sustain guideline 
practice.
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Evidence-based quality management 
of preanalytical phase
The effective management of preanalytical phase is only 
possible through consistently and continuously apply-
ing the evidence-based approach in everyday routine 
laboratory activity. Evidence-based approach means that: 
1)  laboratory processes are closely monitored; 2) there is 
an operational and functional error detection system in 
place; and 3) root-cause analysis is done whenever there 
is an increase in error frequency, as a part of the continu-
ous quality improvement. Evidence-based approach pre-
sumes that all preanalytical steps are scrutinized and 
challenged by some of the below questions:
 – Is this procedure in accordance with the recom-
mended, i.e., the best possible practice?
 – Is there evidence to support the use of a given 
procedure?
 – Do I know the limitations of this procedure?
 – Do I know how this procedure affects sample quality 
and test results?
 – Do I know how to control potential sources of variabil-
ity related to this procedure?
 – How is this procedure contributing to the patient care 
and how does it affect patient outcome?
The management of preanalytical phase should encom-
pass all steps of the total testing process which take place 
before the analytical part, and hence include test request-
ing, patient preparation, sample collection, transport, 
delivery to the laboratory and handling. Each of those 
steps is potentially associated with numerous sources 
of variability and some chance of error. By effective evi-
dence-based management of preanalytical phase, the 
laboratory can reduce the error rate and improve care for 
patient as well as clinical outcome [84]. For example, an 
evidence based approach to test requesting means that 
test requesting patterns are assessed for their appropri-
ateness for each particular patient population and patient 
condition, by both reducing the rate of unnecessary test 
requests and ensuring that the right test is requested 
for the right patient (i.e., adequate utilization of tests 
which are necessary/useful in a specific patient popula-
tion) [85]. To properly manage the test demand, a labora-
tory should, as already discussed in depth above (under 
section: ‘Unnecessary laboratory tests – a matter of 
concern?’), challenge the current test panel used for a 
certain condition by questioning whether such panel is in 
accordance with the recommended diagnostic algorithm 
and how this testing panel affects patient outcome. Some 
paradigmatic examples are: ‘Is procalcitonin a useful 
diagnostic marker for the diagnosis of sepsis?’; ‘What is 
the best biomarker for diagnosis of acute kidney failure?’; 
and ‘What is the best strategy to diagnose urinary tract 
infection?’
If diagnostic algorithm and guidelines for a certain 
condition are unavailable, the laboratory should 
search for the evidence supporting the use of a certain 
test or a panel of tests in a particular patient group. As 
already discussed, numerous interventions have been 
proposed to address and manage appropriate test uti-
lization. Such interventions are effective tools aimed 
to reduce costs and waste and improve the patient 
outcome. It has been demonstrated that through the 
active intervention by the laboratory staff and bi-
directional communication with clinicians a signifi-
cant savings and reduction in the use of tests can be 
achieved [86].
Another good example of the evidence-based quality 
management approach to the preanalytical phase is the 
implementation and use of sample acceptance crite-
ria in a laboratory. Many laboratories have established 
their criteria for sample acceptance or rejection. Instead 
of being evidence based, those criteria are unfortu-
nately quite often based on manufacturer’s declara-
tions, expert opinion or historical reasons. They are only 
limited examples of sharing acceptance criteria on a 
national basis [87, 88]. Therefore, the crucial question 
is to establish whether those criteria are correct or not, 
and if they really fit for the purpose. Another good point 
is to find what each laboratory can do to improve the 
policy for assessing sample quality. Again, the labora-
tory should challenge its current policy by examining if 
the procedure in use is recommended by some authority, 
or whether there is evidence to support the use of that 
particular procedure. Most importantly, the laboratory 
should investigate how the procedure in use affects the 
patient outcome. Not a single step should be taken for 
granted. Not a single decision should be made in the lack 
of proper evidence.
Unfortunately, the laboratory often faces the lack 
of evidence in cases when there is a need to address a 
certain preanalytical issue or problem. When evidence 
does not exist, the laboratory should perform its own 
validation or verification study to address the issues 
of interest. This consumes time, money and other 
resources. Obviously, there is a need for a global joint 
effort of laboratory professionals in sharing experiences 
and addressing some common preanalytical issues and 
problems, to mutually benefit from each other and over-
come this problem.
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Conclusions
The management of quality in preanalytical laboratory 
practices is a challenging enterprise, which requires coor-
dinated efforts from both a universal and local perspective 
[89]. After several years of research in the field of quality 
of laboratory diagnostics, recognizing the iceberg of labo-
ratory errors and acknowledging that extra-analytical 
quality is at least as important as analytical quality are 
vital to achieve substantial improvement of laboratory 
diagnostics and patients safety (Figure 1) [90, 91]. There-
fore, we sincerely hope that this collective paper would 
enable the exchange of ideas and knowledge related to 
some most common issues and everyday problems, and 
ultimately enhance harmonization [92] and quality in the 
preanalytical phase.
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